Search Results
KRYSTAL-1 and CodeBreak 100: targeting KRAS G12C in lung cancer
KRYSTAL-1: adagrasib for KRAS-mutant NSCLC
KRYSTAL-1: activity of adagrasib in KRASG12m NSCLC with untreated CNS metastases
ASCO 2021 Lung Recap: CodeBreak 100: Sotorasib in KRAS G12C Mutation
KRYSTAL-1: next steps in the field of KRASG12C-mutant cancers
#ESMO21 Highlights on adagrasib in patients with KRASG12C-mutated CRC: The KRYSTAL-1 study
Phase II CodeBreak 100 trial of sotorasib in advanced NSCLC
KRYSTAL-1: Adagrasib as monotherapy or combined with cetuximab in patients with CRC harboring a ...
Key lung cancer updates: KRAS(G12C) inhibitors and ADCs
KRAS G12C Inhibition in Advanced NSCLC: AMG 510
Overall survival in the Phase II CodeBreaK 100 trial in NSCLC
KRAS G12C Inhibition in Advanced NSCLC: MRTX849
